CN104906590A - 含巴西蜡的沃尼妙林注射液 - Google Patents
含巴西蜡的沃尼妙林注射液 Download PDFInfo
- Publication number
- CN104906590A CN104906590A CN201510232770.3A CN201510232770A CN104906590A CN 104906590 A CN104906590 A CN 104906590A CN 201510232770 A CN201510232770 A CN 201510232770A CN 104906590 A CN104906590 A CN 104906590A
- Authority
- CN
- China
- Prior art keywords
- valnemulin
- injection
- liter
- preparation
- brazil wax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LLYYNOVSVPBRGV-MVNKZKPCSA-N valnemulin Chemical compound CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 LLYYNOVSVPBRGV-MVNKZKPCSA-N 0.000 title claims abstract description 72
- 229950008166 valnemulin Drugs 0.000 title claims abstract description 72
- 239000004203 carnauba wax Substances 0.000 title claims abstract description 49
- 238000002347 injection Methods 0.000 title claims abstract description 49
- 239000007924 injection Substances 0.000 title claims abstract description 49
- 235000013869 carnauba wax Nutrition 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 claims abstract description 82
- MFBPRQKHDIVLOJ-AFFLPQGKSA-N 133868-46-9 Chemical compound Cl.CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 MFBPRQKHDIVLOJ-AFFLPQGKSA-N 0.000 claims abstract description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000003513 alkali Substances 0.000 claims abstract description 38
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims abstract description 36
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims abstract description 28
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims abstract description 28
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims abstract description 28
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 22
- 239000001087 glyceryl triacetate Substances 0.000 claims abstract description 18
- 235000013773 glyceryl triacetate Nutrition 0.000 claims abstract description 18
- 229960002622 triacetin Drugs 0.000 claims abstract description 18
- 229960002903 benzyl benzoate Drugs 0.000 claims abstract description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 10
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 5
- 239000001509 sodium citrate Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 11
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 11
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 7
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 6
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000000473 propyl gallate Substances 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 229940075579 propyl gallate Drugs 0.000 claims description 3
- QSHVAZMOLNGWSY-UHFFFAOYSA-N 3-butyl-4-methoxyphenol Chemical group CCCCC1=CC(O)=CC=C1OC QSHVAZMOLNGWSY-UHFFFAOYSA-N 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- XYQRXRFVKUPBQN-UHFFFAOYSA-L Sodium carbonate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]C([O-])=O XYQRXRFVKUPBQN-UHFFFAOYSA-L 0.000 abstract 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 abstract 1
- 229940001593 sodium carbonate Drugs 0.000 abstract 1
- 229940018038 sodium carbonate decahydrate Drugs 0.000 abstract 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 abstract 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 13
- 241001494479 Pecora Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 238000013019 agitation Methods 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000010241 blood sampling Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 230000003578 releasing effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- -1 benzyl alcohol benzyl ester Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000204003 Mycoplasmatales Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000011182 sodium carbonates Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
采血时间(h) | 10mg/kg b.w. | 20mg/kg b.w. | 30mg/kg b.w. |
0.5 | 597 | 753 | 1261 |
1.5 | 936 | 1296 | 1431 |
3 | 1235 | 1368 | 1626 |
12 | 431 | 835 | 763 |
24 | 346 | 679 | 601 |
48 | 135 | 464 | 417 |
72 | 64 | 255 | 334 |
96 | 未检测到 | 112 | 189 |
测定时间(天) | 实施例1制剂 | 实施例2制剂 | 实施例3制剂 | 实施例4制剂 |
30 | 0.21 | 0.09 | 0.35 | 0.17 |
90 | 0.64 | 0.12 | 0.33 | 0.39 |
180 | 0.92 | 0.84 | 0.56 | 0.61 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510232770.3A CN104906590B (zh) | 2015-05-11 | 2015-05-11 | 含巴西蜡的沃尼妙林注射液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510232770.3A CN104906590B (zh) | 2015-05-11 | 2015-05-11 | 含巴西蜡的沃尼妙林注射液 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104906590A true CN104906590A (zh) | 2015-09-16 |
CN104906590B CN104906590B (zh) | 2017-09-15 |
Family
ID=54076297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510232770.3A Active CN104906590B (zh) | 2015-05-11 | 2015-05-11 | 含巴西蜡的沃尼妙林注射液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104906590B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105878176A (zh) * | 2016-04-06 | 2016-08-24 | 山东胜利生物工程有限公司 | 一种盐酸沃尼妙林注射用原位凝胶制剂及其制备方法 |
CN108853022A (zh) * | 2017-05-16 | 2018-11-23 | 北京科百大科技有限责任公司 | 一种稳定的盐酸沃尼妙林组合物的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1444925A (zh) * | 2002-03-19 | 2003-10-01 | 王玉万 | 含乙基纤维素的兽用长效注射制剂 |
CN1461639A (zh) * | 2002-05-31 | 2003-12-17 | 王玉万 | 含氢化蓖麻油/治疗药物固体分散体微粒的缓释注射剂 |
CN102001980A (zh) * | 2010-10-27 | 2011-04-06 | 齐鲁动物保健品有限公司 | 一种沃尼妙林盐酸盐的出料方法 |
CN103520099A (zh) * | 2013-10-30 | 2014-01-22 | 王玉万 | 含有效成份为沃尼妙林的长效注射剂 |
-
2015
- 2015-05-11 CN CN201510232770.3A patent/CN104906590B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1444925A (zh) * | 2002-03-19 | 2003-10-01 | 王玉万 | 含乙基纤维素的兽用长效注射制剂 |
CN1461639A (zh) * | 2002-05-31 | 2003-12-17 | 王玉万 | 含氢化蓖麻油/治疗药物固体分散体微粒的缓释注射剂 |
CN102001980A (zh) * | 2010-10-27 | 2011-04-06 | 齐鲁动物保健品有限公司 | 一种沃尼妙林盐酸盐的出料方法 |
CN103520099A (zh) * | 2013-10-30 | 2014-01-22 | 王玉万 | 含有效成份为沃尼妙林的长效注射剂 |
Non-Patent Citations (1)
Title |
---|
董吉等: "注射型原位凝胶植入剂的研究进展", 《药学进展》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105878176A (zh) * | 2016-04-06 | 2016-08-24 | 山东胜利生物工程有限公司 | 一种盐酸沃尼妙林注射用原位凝胶制剂及其制备方法 |
CN105878176B (zh) * | 2016-04-06 | 2019-01-08 | 山东胜利生物工程有限公司 | 一种盐酸沃尼妙林注射用原位凝胶制剂及其制备方法 |
CN108853022A (zh) * | 2017-05-16 | 2018-11-23 | 北京科百大科技有限责任公司 | 一种稳定的盐酸沃尼妙林组合物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104906590B (zh) | 2017-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101959501B (zh) | 稳定的含多西紫杉醇的单液药用组合物 | |
CN101444542B (zh) | 引藻萃取物 | |
AU2016258642B2 (en) | Cabazitaxel fat emulsion injection, and preparation method and use thereof | |
CN104069084B (zh) | 一种质量稳定的度他雄胺软胶囊 | |
CN104906590A (zh) | 含巴西蜡的沃尼妙林注射液 | |
CA2872001A1 (en) | Lactate-based oily formulation of fulvestrant or derivative thereof and method for producing the same | |
CN104922668A (zh) | 一种稳定的抗vegf抗体制剂及其用途 | |
CN105030685B (zh) | 一种恩杂鲁胺固体分散体口服制剂 | |
CN102940630A (zh) | 含有西罗莫司酯化物的药物组合物及其制备方法 | |
CN103816126B (zh) | 一种含有丁溴东莨菪碱的药物组合物 | |
CN103550150B (zh) | 改进的含二甲基硅油的注射剂 | |
CN101703489B (zh) | 恩替卡韦软胶囊 | |
CN102636600A (zh) | 一种测定盐酸帕洛诺司琼组合物中光学异构体的方法 | |
CN104906591B (zh) | 一种泰妙菌素胶体注射剂及其制备方法 | |
CN106377498A (zh) | 含三乙酸甘油酯、苯甲酸苄酯和蓖麻油的抗寄生虫注射剂 | |
JP2017057202A (ja) | ボルテゾミブ含有凍結乾燥医薬組成物およびその製造方法 | |
US10064883B2 (en) | Lipiodol-based anti-tumour emulsion for treating cancer | |
CN104606135A (zh) | 一种含多西他赛的组合物及其制备方法 | |
CN106880597A (zh) | 一种依维莫司片 | |
CN103071146A (zh) | 醋酸卡泊芬净组合物及其制备方法 | |
CN105616365B (zh) | 一种依维莫司片剂 | |
CN103191057A (zh) | 头孢噻呋的水性悬浮注射液及其制备方法 | |
JP6285725B2 (ja) | エタノールフリードセタキセル医薬組成物 | |
CN102697720B (zh) | 盐酸伊立替康脂质纳米粒注射剂 | |
CN105136956A (zh) | 一种快速测定瑞戈非尼含量的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171212 Address after: No. 16, No. 37, yard No. 16, No. 37, super front road, Beijing science and Technology Park, Beijing Patentee after: Beijing Zhongnonghuawei Technology Group Co.,Ltd. Address before: 102206 Boya C, No. 4, hospital No. 4, Zhongguancun life science Road, Zhongguancun, Beiqing Road, Beijing City, 510 Patentee before: Wang Yuwan |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240320 Address after: 435300 Jinshan Road, Hexi Lishizhen Pharmaceutical Industrial Park, Qichun County, Huanggang City, Hubei Province, No. 008-8 Patentee after: Hubei Shizhen Health Research Co.,Ltd. Country or region after: Zhong Guo Address before: 102299 no.c2033, 2 / F, building 16, No.37 courtyard, Chaoqian Road, science and Technology Park, Changping District, Beijing Patentee before: Beijing Zhongnonghuawei Technology Group Co.,Ltd. Country or region before: Zhong Guo |